Trial Profile
A Phase I/II Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 May 2023
Price :
$35
*
At a glance
- Drugs Zirconium-89 DFO-MSTP 2109A (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Diagnostic use; Pharmacokinetics
- 03 May 2023 Status changed from active, no longer recruiting to completed.
- 01 Feb 2023 Planned End Date changed from 1 Jan 2023 to 1 Jan 2024.
- 01 Feb 2023 Planned primary completion date changed from 1 Jan 2023 to 1 Jan 2024.